Antiangiogenic therapy-evolving view based on clinical trial results

Nature Reviews Clinical Oncology

Volumn 9, Issue 5, 2012, Pages 297-303

  Jayson, Gordon C ^a   Hicklin, Daniel J ^b   Ellis, Lee M ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; PAZOPANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG RESPONSE; FISTULA; GENE MUTATION; GENETIC STABILITY; GLIOBLASTOMA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; THROMBOEMBOLISM; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84860366086     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.8     Document Type: Review

References (71)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
2. Langer, R., Brem, H., Falterman, K., Klein, M. & Folkman, J. Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193, 70-72 (1976).
3. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997). (Pubitemid 28027321)
4. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997). (Pubitemid 28015876)
5. Brem, H. & Folkman, J. Analysis of experimental antiangiogenic therapy. J. Pediatr. Surg. 28, 445-451 (1993). (Pubitemid 23091058)
6. Citeline. TrialTrove [online], http://informa.citeline.com (2012).
7. National Cancer Institute. Angiogenesis inhibitors-factsheet [online], http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors (2011).
8. Cannistra, S. A. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180-5186 (2007). (Pubitemid 350232248)
9. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
10. Jayson, G. C. et al. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab [abstract 804]. Eur. J. Cancer 47 (Suppl. 1), S96 (2011).
11. Miles, D. et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with HER2-negative metastatic breast cancer [abstract P2-16-04]. Cancer Res. 70 (Suppl.), 235 (2010).
12. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
13. Kristensen, G. et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), LBA5006 (2011).
14. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
15. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003). (Pubitemid 36910021)
16. Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
17. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
18. National Cancer Institute. FDA approval for bevacizumab [online], http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab (2011).
19. Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
20. Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622 (2010).
21. Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237 (2009).
22. Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract]. J. Clin. Oncol. 28 (Suppl.), LBA4511 (2010).
23. Martin, M. et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 12, 369-376 (2011).
24. Spigel, D. R. et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 2582-2589 (2011).
25. Scagliotti, G. et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non small cell lung cancer. J. Clin. Oncol. 28, 1835-1842 (2010).
26. Cheng, A. et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a4000 (2011).
27. Sanofi-Aventis. Sanofi-Aventis and Regeneron report top-line results from phase III study with aflibercept (VEGF Trap) in second-line non-small cell lung cancer [online], http://www.sanofi.co.uk/l/gb/medias/57180F97-E9EB-4FA1-A508- 77091E3164C4.pdf (2011).
28. Van Cutsem, E. et al. Intravenous (IF) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): results of a multinational phase III trial (EFC10262-VELOUR) [abstract]. Ann. Oncol. 22 (Suppl. 5), aO-0024 (2011).
29. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
30. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
31. O'Connor, J. P. et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res. 15, 6674-6682 (2009).
32. Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005). (Pubitemid 40775678)
33. Wedam, S. B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769-777 (2006). (Pubitemid 46622044)
34. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004). (Pubitemid 38524883)
35. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin 1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004). (Pubitemid 40017699)
36. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007). (Pubitemid 46075199)
37. Jackson, A., O'Connor, J. P., Parker, G. J. & Jayson, G. C. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin. Cancer Res. 13, 3449-3459 (2007). (Pubitemid 46955104)
38. Li, J. L. et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71, 6073-6083 (2011).
39. Duff, S. E. et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur. J. Cancer 42, 112-117 (2006). (Pubitemid 41814541)
40. Smith, N. R. et al. Vascular endothelial growth factor receptors VEGFR 2 and VEGFR 3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 16, 3548-3561 (2010).
41. Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828 (2010).
42. Medici, D. et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406 (2010).
43. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotech. 25, 911-920 (2007). (Pubitemid 47236916)
44. Grothey, A. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326-5334 (2008).
45. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00700102 (2011).
46. Shojaei, F. et al. G CSF initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742-6747 (2009).
47. Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702-711 (2011).
48. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 10, 1096-1103 (1996). (Pubitemid 26338628)
49. Murukesh, N., Dive, C. & Jayson, G. C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8-18 (2010).
50. Gourley, C. et al. Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens [abstract]. J. Clin. Oncol. 29 (Suppl.), a5000 (2011).
51. Jubb, A. M. et al. Impact of vascular endothelial growth factor A expression, thrombospondin 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24, 217-227 (2006). (Pubitemid 46622051)
52. Fabi, A. et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin. Cancer Res. 17, 2055-2064 (2011).
53. Van Cutsem, E. et al. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study [abstract]. ASCO Gastrointestinal Cancers Symp. a117 (2009).
54. Kang, Y. et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract]. J. Clin. Oncol. 28 (Suppl. 18), LBA4007 (2011).
55. Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007). (Pubitemid 47325606)
56. Mitchell, C. L. et al. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann. Oncol. 21, 1982-1989 (2010).
57. RECIST. RECIST 1.1 [online], http://www.recist.com/index.html (2010).
58. Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753-1759 (2007). (Pubitemid 46797957)
59. O'Connor, J. P., Jackson, A., Parker, G. J. & Jayson, G. C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96, 189-195 (2007). (Pubitemid 46160619)
60. O'Connor, J. P. et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX 6. Br. J. Cancer 105, 139-145 (2011).
61. Shojaei, F., Singh, M., Thompson, J. D. & Ferrara, N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl Acad. Sci. USA 105, 2640-2645 (2008). (Pubitemid 351520566)
62. You, W. K. et al. VEGF and c Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-4768 (2011).
63. Hanrahan, E. O. et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 28, 193-201 (2010).
64. Leenders, W. P. et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222-6230 (2004). (Pubitemid 39287530)
65. Pezzella, F. et al. Non small cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151, 1417-1423 (1997). (Pubitemid 27479772)
66. Stessels, F. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 90, 1429-1436 (2004). (Pubitemid 38586273)
67. Sardari Nia, P., Hendriks, J., Friedel, G., Van Schil, P. & Van Marck, E. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. Histopathology 51, 354-361 (2007). (Pubitemid 47301631)
68. Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64, 8249-8255 (2004). (Pubitemid 39491762)
69. Sheldon, H. et al. New mechanism for notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 116, 2385-2394 (2010).
70. Miller, K. D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin. Breast Cancer 3, 421-422 (2003). (Pubitemid 36395551)
71. Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).